Chinese scientists publish promising findings on clinical trials involving Avasimibe, which has shown to inhibit tumour growth by targeting FoxM1-AKR1C1 in osteosarcoma
Cancer Australia has released initial National Data on Australian paediatric cancer stages at diagnosis, including the rare and aggressive Sarcoma cancers.
This data covers sixteen major cancer types, which represent approximately three-quarters of all childhood cancers diagnosed in Australia. To see more please see ASSG’s press release or visit
On the 21st of February Biosceptre’s proposed Phase I clinical trial for BIL06v (anti-cancer vaccine) was granted conditional approval by the Bellberry Ethics committee. Biosceptre is now proceeding to take BIL06v into a Phase I trial in late Q2 or early Q3 2018.
Biosceptre has high confidence in the safety of BIL06v, in part as a result of pre-clinical studies and compassionate access patients treated in Australia under the TGA’s Special Access Scheme.
The planned clinical trial will recruit between 20 and 30 patients from a basket of late stage cancers and seeks to confirm safety, tolerability and immunogenicity of BIL06v. The planned clinical trial will also seek to identify early indications of efficacy in humans.
CEO Gavin Currie said “Having recently closed entry to our Series A fund raising round, we are pleased that this fully funded clinical trial, building on significant preclinical data, has been conditionally approved. We consider that a successful clinical trial, our first for a systemic therapeutic product targeting nfP2X7, will provide further validation of nfP2X7. We are hopeful for first patient recruitment in Q2 2018.”
Read more about the very promising developments regarding the BIL06v anti-cancer vaccine and nfP2X.
Using whole-genome sequencing to research deeply into our DNA has led to the discovery that all disease is linked to genetic mutations so that instead of trying to treat disease symptoms, we can now target the mutations causing them. This is personalised medicine. Read more about the outstanding work of the Garvan Institute, providing untold hope for sarcoma patients.
The sarcoma research group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Òscar Martínez-Tirado, has identified a potential new therapeutic target for Ewing sarcoma, the second most frequent bone cancer in children and adolescents, and a tumour known by its aggressiveness and tendency to metastasise.